Category Archives: Uncategorized

New Partnership in Russia and CIS Further Expands Footprint for EffRx Proprietary Technologies

Freienbach, Switzerland, January 13, 2015 – EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for a variety of orphan and specialty indications, today announced the signing of an agreement with Andrus Ltd. to develop products for commercialization in Russia and CIS countries.

“We are excited to further expand the footprint of our proprietary technologies with the development of novel therapeutic entities for these fast-growing emerging markets” said Christer Rosén, EffRx Chief Executive Officer. “Although our core focus within EffRx is to develop our own un-encumbered orphan products we will still utilize this business segment to generate a steady increasing revenue stream.”

Under the terms of the agreement EffRx will develop novel, tailored therapeutic entities (6 products are presently identified) for commercialization by Andrus in Russia and CIS countries. “We are excited to expand our partnership with Andrus beyond our earlier agreement with Binosto®, our first approved product for osteoporosis, and to bring new products that will address an unmet medical need in these countries” said Christer Rosén.

—————————————————

About EffRx Pharmaceuticals
EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that develops novel therapeutic entities including orphan indications by applying its proprietary technology platform to well characterized molecules. EffRx developments focus at improving the quality of life of patients with unmet medical needs.

About Andrus Ltd.
Andrus Ltd. is dedicated to creating a novel Russian biopharmaceutical platform by bridging the gap between novel biopharmaceutical technologies and the Russian Healthcare market. Through partnering with leading development companies and leveraging Andrus’ domestic operations, the Company is able to build a healthcare platform based on best in class science and drug development.

EffRx Signs Binosto® Distribution Agreements in Russia and Africa

New Partnerships Significantly Expand Global Footprint for Proprietary Buffered Effervescent Osteoporosis Therapy

Freienbach, Switzerland — EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced the signing of two new distribution agreements that will bring its osteoporosis treatment, Binosto®, to strategic markets in Russia, CIS countries and Africa.

“We are excited to expand the global footprint of Binosto® with the addition of these fast-growing emerging markets”

EffRx has partnered with Andrus, Ltd. to distribute Binosto® in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. Through another partnership, with Adcock Ingram Heathcare (Pty) Ltd., Binosto® will be available in South Africa, Namibia, Botswana, Swaziland, Lesotho, Zimbabwe, Kenya and Ghana.

EffRx’s first commercial product, Binosto®, is a buffered, effervescent formulation of alendronate, the most broadly prescribed treatment for osteoporosis. The product was approved by the U.S. Food & Drug Administration in 2012. With these agreements, Binosto® will be commercially available in 53 countries worldwide.

“We are excited to expand the global footprint of Binosto® with the addition of these fast-growing emerging markets,” said Lorenzo Bosisio, EffRx Chief Commercial Officer. “Binosto® is our first approved product and provides an important proof of concept for our development pipeline of novel therapeutic entities, and we look forward to making it available to an increasing population with these two agreements.”

“The continued worldwide adoption of Binosto® is the first of our current out-licensing initiatives and is expected to provide a steady income stream in the future. We continue to focus on the two other, potentially larger, elements of our threefold growth strategy – products in the orphan drug segment, including the ongoing development of our PCOS product, and lifecycle management,” said Christer Rosén, EffRx Chairman and Chief Executive Officer.

EffRx signs distribution agreements for Binosto® in Italy, Spain and Portugal

Freienbach, February 4th 2014 – EffRx Pharmaceuticals S.A. today announced that it has signed exclusive distribution agreements with three leading local pharmaceutical companies in Italy, Spain and Portugal for Binosto® – EffRx’s innovative osteoporosis medication. Under the terms of the agreement, EffRx grants exclusive marketing authorization and distribution rights to Abiogen Pharma SpA. for Italy, Lacer S.A. for Spain, and Laboratorios Atral S.A. for Portugal.

Binosto® is the first and only buffered solution for the treatment of osteoporosis, delivering fracture-risk reduction at the hip & spine. Binosto is administered as an effervescent tablet for oral solution and offers convenience for the patient. Binosto is currently marketed in the United States, and approved in Europe and Australia; approvals in other territories are pending. Binosto® was originally developed by EffRx through an agreement with Merck & Co, Inc. granting EffRx worldwide rights to all Merck effervescent and related patents protecting alendronate.

EffRx expects the launch in these markets beginning in the second quarter 2014. Italy, Spain and Portugal are 3 major markets for osteoporosis treatment in Europe. EffRx is confident that the promise of Binosto® will also become true in other European countries with the appointment of distribution partners that have a sizeable footprint as well as in-depth understanding of their local markets.

Christer Rosén, Chairman and CEO of EffRx Pharmaceuticals said, “We are thrilled to announce the partnerships with Abiogen, Lacer, and Atral.  These partners, with their well-established sales forces, are well positioned to drive Binosto® to a market leadership position.”

EffRx is committed to making Binosto® available to osteoporosis patients around the world and is currently discussing the commercialization of Binosto® with pharmaceutical companies in other key Regions and countries.

About EffRx Pharmaceuticals
EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that exploits its proprietary technology platform to create novel therapeutic entities.

EffRx strives to make existing good medicines better and thereby improve the quality of life of patients. EffRx targets improvements to leading medications, focused on tolerability, absorption, compliance and convenience, thus creating best in class products.

EffRx has established its proprietary pipeline in metabolic bone disease and pediatric medications and is presently aggressively expanding its product portfolio.

Enquiries
Lorenzo Bosisio
lbosisio@effrx.com
+41 44 503 7867

EffRx signs distribution agreement with Ahn-Gook Pharma for Binosto® for Korea

Freienbach, 03 June 2013 – EffRx Pharmaceuticals S.A. today announces the signing of an exclusive distribution agreement with Ahn-Gook Pharmaceutical Co. Ltd for Binosto – EffRx’s innovative osteoporosis medication for the Korean market.

Under the terms of the agreement, EffRx grants exclusive rights to Ahn-Gook to register, market and distribute Binosto® in South Korea. This agreement will leverage Ahn-Gook’s strong local presence and expertise in Korea.

Binosto® is the first and only buffered solution for the treatment of osteoporosis, delivering fracture-risk reduction at the hip & spine and offering the potential to improve adherence to therapy. Binosto® is taken with a small amount of water and lowers gastric acidity in the first 30 minutes after administration, a time when the patient must not eat or drink anything other than plain water.

Christer Rosen, EffRx Chairman and CEO said at the signing ceremony “We are pleased to initiate a partnership with Ahn-Gook who has a dynamic and outstanding sales force, and we are convinced that Ahn-Gook becomes a new strong player in the Korean osteoporosis market.

Jin Auh, Ahn-Gook President & CEO said that the Korean market is worth 140M USD, and bisphosphonates account for more than 90%. “We highly expect Binosto® to overcome limitations of current bisphosphonates”

Binosto is expected to be registered in Korea in 2014 and launched within the same year.

 

Enquiries
Lorenzo Bosisio
+41 44 503 7867
 

About Binosto®
Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution and has been approved in the United States, Europe and Australia for the treatment of osteoporosis. It has been marketed since October 2012 in the United States by Mission Pharmacal, and is expected to be launched in other territories in 2014.

Binosto has been developed with EffRx innovative patented effervescent technology. EffRx is operating under exclusive worldwide rights to all effervescent and related patents of alendronate licensed from Merck & Co, Inc.

About EffRx
EffRx Pharmaceuticals SA is an innovative specialty pharmaceutical company that exploits its proprietary technology platform to improve the efficacy, tolerability and convenience of medicines, thereby generating better products and improving quality of life for patients.  The primary focus is on metabolic bone disease, pediatric medications and supporting larger companies in Life Cycle Management. 

About Ahn-Gook
Ahn-Gook Pharmaceutical Co., Ltd. is a Korea-based pharmaceutical company. The Company’s products include respiratory agents, gastrointestinal agents, anti-inflammatories, analgesics, ophthalmics and circulatory system agents. It also provides antibiotics, antifungal drugs, antihyperlipidemics, antiallergic drugs, anti-diabetic drugs, urinary system drugs and skin disease remedies. Anh-Gook also markets OTC and ethical drugs.

Disclaimer
Please refer to the official Binosto® Prescribing Information and approved indications, contraindications, and warnings in your country.

Agreement with Hikma Pharmaceuticals

EffRx signs a distribution agreement with Hikma Pharmaceuticals for Binosto® in MENA

Freienbach, 4 February 2013 – EffRx Pharmaceuticals SA today announces the signing of a distribution agreement with Hikma Pharmaceuticals for Binosto®, EffRx’s innovative osteoporosis medication, for the Middle East and North Africa (“MENA”) region.  Binosto® is the first and only buffered solution for the treatment of osteoporosis, delivering fracture-risk reduction and offering the potential to improve adherence to therapy.  

Under the terms of the agreement, EffRx grants the exclusive rights to Hikma to register, market and distribute Binosto® in 19 countries across MENA.  The agreement will leverage Hikma’s strong local presence and regulatory expertise in MENA, with over 1,600 sales and marketing representatives across the region. 

Binosto® was developed by EffRx through an agreement with Merck & Co, Inc. granting EffRx the worldwide rights to all effervescent and related patents of alendronate.   Patents have been granted to EffRx providing exclusivity for Binosto® through February 2023.  Additional patents are pending.   Binosto (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution and has recently been approved in the United States, Europe and Australia[1] for the treatment of osteoporosis in postmenopausal women.  In the United States it is also approved for the treatment of men with osteoporosis to increase bone mass.  Approvals in other territories are pending.

Mazen Darwazah, Hikma’s Vice Chairman and CEO of MENA said, “We are pleased to be licensing this excellent product from EffRx.  The agreement supports our strategy to continue working with global partners to strengthen our product portfolio in growing therapeutic categories, including women’s health.  Hikma is committed to bringing a broad range of high quality, pharmaceutical products to patients in MENA.”  

Christer Rosén, Chairman and CEO of EffRx Pharmaceuticals said, “We are thrilled to announce this partnership with Hikma, a company who we believe to be an ideal partner for EffRx in MENA.  We believe Hikma’s well-established sales force across the region can drive Binosto® to a market leadership position and we are extremely proud to have Hikma as a partner.”

EffRx is currently discussing the commercialization of Binosto with pharmaceutical companies in other key Regions. Lorenzo Bosisio, VP Business Development said, “This agreement is an important milestone for EffRx. It comes just after the recently announced reacquisition of rights to Binosto from Takeda. We are very excited about the strong interest for Binosto from partners in the remaining territories, such as Europe, Asia, and Latin America. We are committed to fulfil the promise of Binosto for patients around the world.”